Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report

Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Hongkai, Ma, Zuyi, Wu, Yanxia, Yin, Zi, Jian, Zhixiang, Zhang, Chuanzhao, Hou, Baohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799261/
https://www.ncbi.nlm.nih.gov/pubmed/35117662
http://dx.doi.org/10.21037/tcr.2020.02.45
Descripción
Sumario:Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHOP) chemotherapy alleviated the symptom of plasma cell type of Castleman disease (PCCD) as well as downsized the tumor to provide an opportunity for radical surgical resection. It would contribute to the treatment for borderline resectable or unresectable UCD in the future.

Ejemplares similares